Status:
COMPLETED
Urinary Kidney Injury Molecule-1 (KIM-1) Excretion As Biomarker for Injury in Kidney Transplant Recipients
Lead Sponsor:
Northwell Health
Collaborating Sponsors:
Astellas Pharma US, Inc.
Conditions:
Kidney Transplant Dysfunction
Eligibility:
All Genders
3-18 years
Brief Summary
The purpose of this study is to determine if measuring the level of a protein called Kidney Injury Molecule-1 (KIM-1) in the urine will help healthcare providers detect any problems with the transplan...
Detailed Description
SPECIFIC AIMS: 1. To investigate the role of urinary Kim-1 excretion as a marker of delayed graft function, acute kidney allograft rejection and/or virus-induced allograft nephropathy and/or calcineu...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Children and adults from the age of 3 years who are eligible transplant candidates listed for deceased donor kidney or who are scheduled for a living related or unrelated donor kidney transplant at Mount Sinai Hospital will be eligible for inclusion in this project. Patients will be recruited from the population awaiting kidney transplant treated at the Schneider Children's Hospital and Mount Sinai Hospital.
Exclusion
Key Trial Info
Start Date :
October 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT00805571
Start Date
October 1 2008
Last Update
March 12 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Schneider Children's Hospital
New Hyde Park, New York, United States, 11040